Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
The Journal of Pathology
|
December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas
Karolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
British Journal of Cancer
|
November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
Ashley Weir, Eun-Young Kang, Nicola S Meagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Flurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
Flurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Nicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
Virchows Archiv : an International Journal of Pathology
|
November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Eun Young Kang, Joshua Millstein, Gordana Popovic, et al.
The Journal of Pathology. Clinical Research
|
March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Martin Köbel, Eun-Young Kang, Ashley Weir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Aline Talhouk, Joshy George, Chen Wang, et al.
Nature Communications
|
April 1, 2026
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
Tibor A Zwimpfer, Sian Fereday, Ahwan Pandey, et al.
Cancer
|
December 27, 2022
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Eun-Young Kang, Ashley Weir, Nicola S Meagher, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
The Journal of Pathology
|
December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas
Karolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
British Journal of Cancer
|
November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
Ashley Weir, Eun-Young Kang, Nicola S Meagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Flurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
Flurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Nicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
Virchows Archiv : an International Journal of Pathology
|
November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Eun Young Kang, Joshua Millstein, Gordana Popovic, et al.
The Journal of Pathology. Clinical Research
|
March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Martin Köbel, Eun-Young Kang, Ashley Weir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Aline Talhouk, Joshy George, Chen Wang, et al.
Nature Communications
|
April 1, 2026
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
Tibor A Zwimpfer, Sian Fereday, Ahwan Pandey, et al.
Cancer
|
December 27, 2022
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Eun-Young Kang, Ashley Weir, Nicola S Meagher, et al.
Page
of 4